STOCK TITAN

Immunome Inc. (IMNM) awards RSUs and 62,500 stock options to CBO

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc.’s Chief Business Officer, Kinney Horn, received equity compensation awards. On July 23, 2026, Horn was granted 31,250 shares of common stock underlying RSUs and 62,500 employee stock options with a $22.01 exercise price, vesting over time subject to continuous service, with options expiring July 22, 2036.

Positive

  • None.

Negative

  • None.
Insider Horn Kinney
Role CHIEF BUSINESS OFFICER
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) F2 62,500 $0.00 $0.00
Grant/Award Common Stock F1 31,250 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 62,500 shares (Direct); Common Stock — 31,250 shares (Direct)
Footnotes (2)
  1. F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
  2. F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
RSU grant 31,250 shares Common stock underlying RSUs granted to Chief Business Officer on July 23, 2026
Stock option grant 62,500 options Employee Stock Option (right to buy) granted on July 23, 2026
Option exercise price $22.01 per share Conversion or exercise price for the 62,500 stock options
Option expiration date July 22, 2036 Expiration date of the Employee Stock Option award
RSU vesting rate 25% annually Portion of RSUs vesting each year on the grant-date anniversary, subject to continuous service
Initial option vesting date July 23, 2027 25% of option shares vest on this date, subject to continuous service
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option (right to buy) financial
"Security title reported as Employee Stock Option (right to buy)."
vesting financial
"25% of the RSUs will vest and settle annually on each anniversary."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"Vesting is subject to the Reporting Person's continuous service."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Immunome (IMNM) grant to Kinney Horn?

Immunome granted Chief Business Officer Kinney Horn 31,250 RSUs and 62,500 stock options. The RSUs each represent one share of common stock, while the options carry a $22.01 exercise price and separate time-based vesting conditions.

What are the terms of Kinney Horn's RSU grant at Immunome (IMNM)?

Horn’s RSU grant covers 31,250 shares of Immunome common stock. Each RSU converts into one share upon settlement, with 25% of the RSUs vesting and settling annually on each grant-date anniversary, conditioned on Horn’s continuous service through each vesting date.

How do Kinney Horn's Immunome (IMNM) stock options vest?

Horn’s 62,500 stock options vest over time. 25% of the option shares vest on July 23, 2027, and one‑thirty‑sixth of the remaining shares vests monthly thereafter, in each case subject to his continuous service on each vesting date.

What is the exercise price and expiration date of Kinney Horn's Immunome (IMNM) options?

The granted stock options have a $22.01 per share exercise price and expire on July 22, 2036. These are employee stock options to purchase Immunome common stock, exercisable as they vest over the described schedule.

Is Kinney Horn's Form 4 transaction at Immunome (IMNM) a purchase or a grant?

The Form 4 reports grant/award acquisitions, not open‑market purchases or sales. Horn received RSUs and stock options at a reported price of $0.00 per share, reflecting compensatory awards rather than cash transactions in Immunome stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Horn Kinney

(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100

(Street)
BOTHELL WASHINGTON 98011

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF BUSINESS OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/23/2026A31,250(1)A$031,250D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$22.0107/23/2026A62,500 (2)07/22/2036Common Stock62,500$062,500D
Explanation of Responses:
1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
/s/ Sandra Stoneman, Attorney-in-Fact07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)